Anti-Acetylcholinesterase and Anti-Amnesic Activities of a Pregnane Glycoside, Cynatroside B, from Cynanchum atratum

Abstract

We previously reported that seven pregnane glycosides including cynatroside B isolated from the roots of Cynanchum atratum significantly inhibited acetylcholinesterase (AChE) activity. In the present study, we have characterized the mode of AChE inhibition of cynatroside B, the most potent of these isolated pregnane glycoside inhibitors. We have also examined the anti-amnesic activity of cynatroside B. Cynatroside B inhibited AChE activity in a dose-dependent manner and its IC₅₀ value was 3.6 μM. The mode of AChE inhibition by cynatroside B was reversible and non-competitive in nature. Moreover, cynatroside B (1.0 mg/kg body weight i. p.) significantly ameliorated memory impairments induced in mice by scopolamine (1.0 mg/kg body weight s. c.) as measured in the passive avoidance and the Morris water maze tests. We suggest, therefore, that cynatroside B has both anti-AChE and anti-amnesic activities that may ultimately hold significant therapeutic value in alleviating certain memory impairments observed in Alzheimer's disease.

Cynanchum atratum - Asclepiadaceae - cynatroside B - scopolamine-induced amnesic mice - acetylcholinesterase inhibitory activity - passive avoidance test - Morris water maze test

References

• 1 Bartus R T, Dean R LIII, Beer B, Lippa A S. The cholinergic hypothesis of geriatric memory dysfunction.  Science. 1982;  217 408-14
• 2 Collerton D. Cholinergic function and intellectual decline in Alzheimer's disease.  Neuroscience. 1986;  19 1-28
• 3 Kopelman M D, Corn T H. Cholinergic blockade as a model of cholinergic depletion.  Brain. 1988;  111 1079-110
• 4 Perry E K, Tomlinson B E, Blessed G, Bergman K, Gibson P H, Perry R H. Correlation of cholinergic abnormalities with senile plaques and mental test scores in senile dementia.  Br Med J. 1978;  2 1457-9
• 5 Wilcock G K, Esiri M M, Bowen D M, Smith C CT. Alzheimer's disease: correlation of cortical choline acetyltransferase activity with the severity of dementia and histological abnormalities.  J Neurol Sci. 1982;  57 407-17
• 6 Misane I, Ogren S O. Selective 5-HT(1A) antagonists WAY 100 635 and NAD-299 attenuate the impairment of passive avoidance caused by scopolamine in the rat.  Neuropsychopharmacology. 2003;  28 253-64
• 7 Bejar C, Wang R H, Weinstock M. Effect of rivastigmine on scopolamine-induced memory impairment in rats.  Eur J Pharmacol. 1999;  383 231-40
• 8 Rubaj A, Zgodzinski W, Sieklucka-Dziuba M. The influence of adenosine A3 receptor agonist: IB-MECA, on scopolamine- and MK-801-induced memory impairment.  Behav Brain Res. 2003;  141 11-7
• 9 Lee K Y, Sung S H, Kim Y C. New acetylcholinesterase-inhibitory pregnane glycoside of Cynanchum atratum roots.  Helv Chim Acta. 2003;  86 474-83
• 10 Ellman G L, Courtney K D, Andre V J r, Featherstone R M. A new and rapid colorimetric determination of acetylcholinesterase activity.  Biochem Pharmacol. 1961;  7 88-95
• 11 Kim S R, Hwang S Y, Jang Y P, Park M J, Markelonis G J, Oh T H. et al . Protopine from Corydalis ternata has anticholinesterase and anti-amnestic activities.  Planta Medica. 1999;  65 218-21
• 12 Kim S R, Kang S Y, Lee K Y, Kim S H, Markelonis G J, Oh T H. et al . Anti-amnestic activity of E-p-methoxycinnamic acid from Scrophularia buergeriana .  Cog Brain Res. 2003;  17 454-61
• 13 Kang S Y, Lee K Y, Park M J, Kim Y C, Markelonis G .J, Oh T H. et al . Decursin from Angelica gigas mitigates amnesia induced by scopolamine in mice.  Neurobiol Learn Mem. 2003;  79 11-8
• 14 Morris R G. Development of a water maze procedure for studying spatial learning in the rat.  J Neurosci Meth. 1984;  11 47-60
• 15 Scarpini E, Philip Scheltens P, Feldman H. Treatment of Alzheimer's disease: current status and new perspectives.  Lancet Neurol. 2003;  2 539-47
• 16 Tokita K, Yamazaki S, Yamazaki M, Matsuoka N, Mutoh S. Combination of a novel antidementia drug FK960 with donepezil synergistically improves memory deficits in rats.  Pharmacol Biochem Behav. 2002;  73 511-9
• 17 Chen Z, Xu A J, Li R, Wei E Q. Reversal of scopolamine-induced spatial memory deficits in rats by TAK-147.  Acta Pharmacol Sin. 2002;  23 355-60
• 18 Ogura H, Kosasa T, Araki S, Yamanishi Y, Yamatsu K. Behavioral study of E2020, a novel centrally acting acetylcholinesterase inhibitor.  Soc Neurosci Abstr. 1988;  14 16
• 19 Giacobini E, Zhu X -D, Williams E, Sherman K A. The effects of the selective reversible acetylcholinesterase inhibitor E2020 on extracellular acetylcholine and biogenic amine levels in rat cortex.  Neuropharmacology. 1996;  35 205-11
• 20 Benzi G, Morreti A. Is there a rationale for the use of acetylcholinesterase inhibitors in the therapy of Alzheimer's disease?.  Eur J Pharmacol. 1998;  346 1-13
• 21 Mantle D, Pickering A T, Perry E K. Medicinal plant extracts for the treatment of dementia: A review of their pharmacology, efficacy and tolerability.  CNS Drugs. 2000;  13 201-13